Announcement

Additional Indication (For relief of local pain associated with rheumatoid arthritis) Approved for “MOHRUS Tape,” a topical analgesic and anti-inflammatory product (Development Code: KPT-220)

On behalf of Hisamitsu Pharmaceutical Co., Inc. (Head office: Tosu City, Saga Pref., President: Hirotaka NAKATOMI), we are pleased to announce that we obtained, under date of November 6, an approval from our health authorities the additional indication, namely, for relief of local pain associated with rheumatoid arthritis, which we had previously applied for in May 2008 regarding “MOHRUS Tape 20 mg” and “MOHRUS Tape L 40 mg” (generic name: ketoprofen, hereinafter “MOHRUS Tape”), a topical analgesic and anti-inflammatory product.

“MOHRUS Tape” obtained “lumbago” as well as “osteoarthritis” and “humeroscapular periarthritis” for the first time in December 1995 as a topical patch for analgesic and anti-inflammatory purposes.

“MOHRUS Tape” has been verified as having a pain-relieving effect in the treatment of rheumatoid arthritis as a nonsteroidal analgesic topical patch and this time around we have obtained regulatory approval for its new indication as referred to above.

As a result of the recent approval given to us, we believe “MOHRUS Tape” will be able to contribute to the relief of local pain associated with rheumatoid arthritis as a new therapeutic option.

References:

Indications of “MOHRUS Tape 20 mg” and “MOHRUS Tape L 40 mg”

- For relief of pain and inflammation in the following disorders when they are accompanied by chronic symptoms (blood flow disorder, myospasm, and muscle contracture): lumbago (muscular and fascial lumbago, spondylosis deformans, discopathy, and sprain of lumber spine), osteoarthritis, humeroscapular periarthritis, tendinitis/tendovaginitis, peritendinitis, and humeral epicondylitis (e.g., tennis elbow).

- For relief of local pain associated with rheumatoid arthritis